The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain

Brain Research

Volumn 744, Issue 2, 1997, Pages 227-234

  Hawkinson, Jon E ^a   Huber, Kirk R ^b   Sahota, Pritam S ^b   Han Hsu, Helen ^b   Weber, Eckard ^a   Whitehouse, M J ^a  

^a Department of Pharmacokinetics and Drug Metabolism   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACEA 1021; cingulate cortex; glycine antagonist; N methyl D aspartate receptor; neuropathology; neurotoxicity; retrosplenial cortex

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; DIZOCILPINE; GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BRAIN; CEREBRAL CORTEX; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLYCINE; MALE; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031023451     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01064-5     Document Type: Article

References (35)

1. Auer, R.N., Assessing structural changes in the brain to evaluate neurotoxicological effects of NMDA receptor antagonists, Psychopharmacol. Bull., 30 (1994) 585-591.
2. Auer, R.N., New structural findings in brain treated with a glycine antagonist, ACEA-1021, J. Cereb. Blood Flow Metab., 15 (Suppl. 1) (1995) S430.
3. Balster, R.L., Mansbach, R.S., Shelton, K.L., Nicholson, K.L., Grech, D.M., Wiley, J.L., Li, H. and Weber, E., Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists, Behav. Pharmacol., 6 (1995) 577-589.
4. 125I-MK-801 binding after subdural hematoma in the rat: an in vivo autoradiographic study, J. Neurosurg., 85 (1996) in press.
5. Duval, D., Roome, N., Gauffeny, C., Nowicki, J.P. and Scatton, B., SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons, Neurosci. Lett., 137 (1992) 193-197.
6. Farber, N.B., Wozniak, D.F., Price, M.T., Labruyere, J., Huss, J., Peter, H.S. and Olney, J.W., Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry, 38 (1995) 788-796.
7. Fix, A.S., Pathological effects of MK-801 in the rat posterior cingulate/retrosplenial cortex, Psychopharmacol. Bull., 30 (1994) 577-583.
8. Fix, A.S., Horn, J.W., Wightman, K.A., Johnson, C.A., Long, G.G., Storts, R.W., Farber, N., Wozniak, D.F. and Olney, J.W., Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)-801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex, Exp. Neurol., 123 (1993) 204-215.
9. Fix, A.S., Long, G.C., Wozniak, D.F. and Olney, J.W., Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: a review, Drug Devel. Res., 32 (1994) 147-152.
10. Hargreaves, R.J., Hill, R.G. and Iversen, L.L., Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology, Acta Neurochir., (Suppl.) 60 (1994) 15-19.
11. Hargreaves, R.J., Rigby, M., Smith, D. and Hill, R.G., Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology, Br. J. Pharmacol., 110 (1993) 36-42.
12. Hargreaves, R.J., Rigby, M., Smith, D., Hill, R.G. and Iversen, L.L., Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism, Neurochem. Res., 18 (1993) 1263-1269.
13. Huber, K., Sahota, P., Kapeghian, J., Han Hsu, H., Amemiya, K., Arthur, A., Tripp, S. and Traina, V., Lack of neuronal vacuolization and necrosis in monkeys treated with Selfotel (CGS 19755), a competitive N-methyl-D-aspartate (NMDA) receptor antagonist, J. Am. College Toxicol. 16 (1997) 1.
14. Keana, J.F.W., Kher, S.M., Cai, S.X., Dinsmore, C.M., Glenn, A.G., Guastella, J., Huang, J.-C., Ilyin, V., Lu, Y., Mouser, P.L., Woodward, R.M. and Weber, E., Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonism of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors, J. Med. Chem., 38 (1995) 4367-4379.
15. Leber, P., Introduction, Psychopharmacol. Bull., 30 (1994) 527-532.
16. Martin, H., Warner, D.S. and Todd, M.M., Effects of glycine receptor antagonism on spreading depression in the rat, Neurosci. Lett., 180 (1994) 285-289.
17. Matsumoto, R.R., Nguyen, D.C. and Truong, D.D., Strychnine-in-sensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder, Eur. J. Pharmacol., 275 (1995) 117-123.
18. McBurney, R.N., Therapeutic potential of NMDA antagonists in neurodegenerative diseases, Neurobiol. Aging, 15 (1994) 271-273.
19. McFarlane, C., Warner, D.S., Nader, A. and Dexter, F., Glycine receptor antagonism: effects of ACEA-1021 on the minimum alveolar concentration for halothane in the rat, Anesthesiology, 82 (1995) 963-968.
20. Meldrum, B.S., The role of glutamate in epilepsy and other CNS disorders, Neurol., 44 (Suppl. 8) (1994) S14-S23.
21. Newell, D.W., Barth, A. and Malouf, A.T., Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures, Brain Res., 675 (1995) 38-44.
22. Olney, J.W., Neurotoxicity of NMDA receptor antagonists: an overview, Psychopharmacol. Bull., 30 (1994) 533-540.
23. Olney, J.W. and Farber, N.B., Glutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry, 52 (1995) 998-1007.
24. Olney, J.W., Labruyere, J. and Price, M.T., Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs, Science, 244 (1989) 1360-1362.
25. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T. and Sesma, M.A., NMDA antagonist neurotoxicity: mechanism and prevention, Science, 254 (1991) 1515-1518.
26. Scatton, B., Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases, Life Sci., 55 (1994) 2115-2124.
27. Sharp, F.R., Butman, M., Aardalen, K., Nickolenko, J., Nakki, R., Massa, S.M., Swanson, R.A. and Sagar, S.M., Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics, Psychopharmacol. Bull., 30 (1994) 555-560.
28. Tricklebank, M.D., Singh, L., Oles, R.J., Preston, C. and Iversen, S.D., The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor, Eur. J. Pharmacol., 167 (1989) 127-135.
29. Tsuchida, E. and Bullock, R., The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA 1021 on ischemic brain damage caused by acute subdural hematoma in the rat, J. Neurotrauma, 12 (1995) 279-288.
30. Warner, D.S., Martin, H., Ludwig, P., McAllister, A., Keana, J.F.W. and Weber, E., In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists, J. Cereb. Blood Flow Metab., 15 (1995) 188-196.
31. Wilding, T.J. and Huettner, J.E., Antagonist pharmacology of kainate-and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors, Mol. Pharmacol., 49 (1996) 540-546.
32. Woodward, R.M., Huettner, J.E., Guastella, J., Keana, J.F.W. and Weber, E., In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites, Mol. Pharmacol., 47 (1995) 568-581.
33. Woodward, R.M., Huettner, J.E., Tran, M., Guastella, J., Keana, J.F.W. and Weber, E., Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist, J. Pharmacol. Exp. Ther., 275 (1995) 1209-1218.
34. Wong, E.H.F. and Kemp, J.A., Sites for antagonism on the N-methyl-D-aspartate receptor channel complex, Annu. Rev. Pharmacol. Toxicol., 31 (1991) 401-425.
35. Zauner, A. and Bullock, R., The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review, J. Neurotrauma, 12 (1995) 547-554.